Vocabria is owned by Viiv Hlthcare.
Vocabria contains Cabotegravir Sodium.
Vocabria has a total of 2 drug patents out of which 0 drug patents have expired.
Vocabria was authorised for market use on 21 January, 2021.
Vocabria is available in tablet;oral dosage forms.
Vocabria can be used as treatment of hiv-1 in an adult in combination with rilpivirine.
Drug patent challenges can be filed against Vocabria from January, 2025.
The generics of Vocabria are possible to be released after 28 April, 2026.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(3 years from now) | |
US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
New Patient Population (NPP) | Mar 29, 2025 |
M | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 in an adult in combination with rilpivirine
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic